SLC7A11 在人类癌症中的预后和临床病理意义：系统评价和荟萃分析。
The prognostic and clinicopathological significance of SLC7A11 in human cancers: a systematic review and meta-analysis.
机构信息
Sichuan University, State Key Laboratory of Biotherapy & Department of Lung Cancer Center and Department of Radiation Oncology, West China Hospital, Chengdu, China.
Sichuan University, State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Pediatric Dentistry, West China Hospital of Stomatology, Chengdu, China.
出版信息
PeerJ. 2023 Feb 27;11:e14931. doi: 10.7717/peerj.14931. eCollection 2023.
OBJECTIVE
It is of great importance to recognize bio-markers for cancer prognosis. However, the association between solute carrier family 7 member 11 (SLC7A11) and prognosis is still controversial. Therefore, we conducted this systematic review and meta-analysis to identify the prognostic and clinicopathological significance of SLC7A11 in human cancers.
METHODS
PubMed, Web of Science, Scopus, the Cochrane Library and Embase database were searched from database inceptions to March 19th 2022. Hand searches were also conducted in references. Prognosis and clinicopathological data were extracted and analyzed.
RESULTS
A total of 12 eligible studies with 1,955 patients were included. The results indicated that SLC7A11 expression is associated with unfavorable overall survival (OS), unfavorable recurrence-free survival (RFS) and unfavorable progression free survival (PFS). And SLC7A11 expression is also associated with more advanced tumor stage.
CONCLUSIONS
SLC7A11 expression is associated with more unfavorable prognosis and more advanced tumor stage. Therefore, SLC7A11 could be a potential biomarker for human cancer prognosis.
目的
识别癌症预后的生物标志物非常重要。然而，溶质载体家族 7 成员 11（SLC7A11）与预后之间的关联仍存在争议。因此，我们进行了这项系统评价和荟萃分析，以确定 SLC7A11 在人类癌症中的预后和临床病理意义。
方法
从数据库建立到 2022 年 3 月 19 日，检索了 PubMed、Web of Science、Scopus、Cochrane Library 和 Embase 数据库。还对参考文献进行了手工检索。提取并分析了预后和临床病理数据。
结果
共纳入 12 项符合条件的研究，共计 1955 例患者。结果表明，SLC7A11 表达与不良总生存期（OS）、不良无复发生存期（RFS）和不良无进展生存期（PFS）相关。并且 SLC7A11 表达也与更晚期的肿瘤分期相关。
结论
SLC7A11 表达与更差的预后和更晚期的肿瘤分期相关。因此，SLC7A11 可能是人类癌症预后的潜在生物标志物。
Zotero 插件